TFA
BPMC

Transamerica Financial Advisors’s Blueprint Medicines BPMC Stock Holding History

Transamerica Financial Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$78 – 1601
2025
Q2 		$78 Hold
1
– – ﹤0.01% 529
2025
Q1 		$1K Hold
1
– – ﹤0.01% 433
2024
Q4 		$1K Hold
1
– – ﹤0.01% 424
2024
Q3 		$1K Hold
1
– – ﹤0.01% 430
2024
Q2 		$1K Hold
1
– – ﹤0.01% 401
2024
Q1 		$1K Hold
1
– – ﹤0.01% 445
2023
Q4 		$1K Hold
1
– – ﹤0.01% 395
2023
Q3 		$1K Hold
1
– – ﹤0.01% 421
2023
Q2 		$1K Hold
1
– – ﹤0.01% 393
2023
Q1 		$1K Sell
1
-40
-98% -$1.8K ﹤0.01% 388
2022
Q4 		$2K Hold
41
– – ﹤0.01% 374
2022
Q3 		$3K Hold
41
– – ﹤0.01% 357
2022
Q2 		$3K Buy
+41
New +$2.4K ﹤0.01% 365

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Transamerica Financial Advisors's BPMC Position: Q3 2025 in Review

Transamerica Financial Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1 share — an estimated $78 sold.

Transamerica Financial Advisors first reported a position in BPMC in Q2 2022 and held it in 13 quarters. The position peaked at $3K in Q3 2022. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Transamerica Financial Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Transamerica Financial Advisors sold 1 Blueprint Medicines share in Q3 2025, an estimated $78.
  • Transamerica Financial Advisors first reported a position in Blueprint Medicines in Q2 2022 and held it in 13 quarters.
  • Transamerica Financial Advisors's Blueprint Medicines position peaked at $3K in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Transamerica Financial Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.